Inventor · disambiguated record
Silke Wissing
Also filed as: WISSING SILKE
6 granted patents·5 pending applications·2 citations·filing 2015–2024
70Inventor score
Top patents by PatentIndex Score
11 records- 0176US12060569B2Inducible AAV REP genesCEVEC PHARMACEUTICALS GMBH·Filed 2023·Granted Aug 13, 2024·0 cites·17 claims
- 0276US10081798B2O-glycan sialylated recombinant glycoproteins and cell lines for producing the sameCEVEC PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 25, 2018·2 cites·8 claims
- 0375US2025011813A1Inducible AAV REP genesCEVEC PHARMACEUTICALS GMBH·Filed 2024·Application pending·0 cites
- 0467US2025002923A1Use of constitutively active variants of growth factor receptors as selection markers for the generation of stable producer cell linesCEVEC PHARMACEUTICALS GMBH·Filed 2024·Application pending·0 cites
- 0561US11685932B2Inducible AAV Rep genesCEVEC PHARMACEUTICALS GMBH·Filed 2018·Granted Jun 27, 2023·0 cites·10 claims
- 0658US10793839B2O-glycan sialylated recombinant glycoproteinsCEVEC PHARMACEUTICALS GMBH·Filed 2018·Granted Oct 6, 2020·0 cites·4 claims
- 0758US2024263148A1Method for the Production of AAVCEVEC PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 0852US12060561B2Use of constitutively active variants of growth factor receptors as selection markers for the generation of stable producer cell linesCEVEC PHARMACEUTICALS GMBH·Filed 2018·Granted Aug 13, 2024·0 cites·11 claims
- 0951US2025270516A1Producer Cell Having Low Levels of VA-RNACEVEC PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 1039US11193156B2Recombinant glycoproteins with reduced antennary fucosylationCevec Pharmaceutical GmbH·Filed 2018·Granted Dec 7, 2021·0 cites·15 claims
- 1136US2019367890A1Cell Line for Producing Recombinant Glycoproteins with Di-Antennary N-Glycans, Methods Using the Same, and Recombinant GlycoproteinsCEVEC PHARMACEUTICALS GMBH·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Silke Wissing files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →